• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >T lymphocyte engineering ex vivo for cancer and infectious disease.
【24h】

T lymphocyte engineering ex vivo for cancer and infectious disease.

机译：T淋巴细胞用于癌症和传染病的离体工程。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Basic research contributions towards the molecular and cellular understanding of immune mediated control of cancer and infectious diseases have created opportunities to develop new forms of T-cell-based vaccination for cancer and chronic infections like HIV. In the past two decades, there has been a dramatic increase in the number of cell therapy clinical trials around the world aimed at enhancing antitumor immunity, restoring immune function to infectious diseases and augmenting vaccine efficacy. OBJECTIVE: To provide a review of new and emerging methods of T lymphocyte engineering, gene transfer to T cells and clinical trials. METHODS: A review of recent clinical trials, along with a brief historical perspective, with a focus on challenges and recent advances in the field and requirements for successful T-cell therapies. CONCLUSION: Advances in the technological approaches and methods for ex vivo manipulation have led to T lymphocytes endowed with enhanced potency and unique functions, with promise as the new generation of infused therapeutics.
机译：背景：对分子和细胞对免疫介导的癌症和传染病控制的分子和细胞理解的基础研究贡献为开发新形式的针对癌症和艾滋病毒等慢性感染的基于T细胞的疫苗接种提供了机会。在过去的二十年中，旨在增强抗肿瘤免疫力，恢复对传染病的免疫功能和增强疫苗功效的细胞疗法临床试验的数量在世界范围内急剧增加。目的：综述T淋巴细胞工程改造，基因转移至T细胞的新方法和临床试验。方法：回顾最近的临床试验，并简要回顾历史，重点关注挑战和最新进展，以及成功的T细胞疗法领域和要求。结论：离体操作的技术方法和方法的进步已导致T淋巴细胞具有增强的效价和独特的功能，有望成为新一代输注疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号